NCT06540066 2026-03-16
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Terminated
BeOne Medicines
BeOne Medicines
Royal Marsden NHS Foundation Trust
Shanghai Junshi Bioscience Co., Ltd.
University of Southern California
University of Chicago
National Cancer Institute (NCI)